Gastrointestinal Cancer Update
by Dr. Neil Love
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇰🇪KE · Science#180500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
150 to 900🎙 Daily cadence·80 episodes·Last published 2mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇰🇪100% - Active Followers
Loyal subscribers who consistently listen
150 to 900
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 18 epsHosts
Recent guests
Recent episodes
Colorectal Cancer — Fifth Annual National General Medical Oncology Summit
Jun 22, 2026
50m 24s
Desmoid Tumors — Microlearning Activity 4 with Prof Bernd Kasper
Jun 22, 2026
23m 46s
Gastroesophageal Cancers — Fifth Annual National General Medical Oncology Summit
Jun 19, 2026
50m 36s
Pancreatic Cancer — Fifth Annual National General Medical Oncology Summit
Jun 15, 2026
44m 49s
Desmoid Tumors — Microlearning Activity 3 with Prof Bernd Kasper
Jun 2, 2026
22m 50s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/22/26 | Colorectal CancerImmune Checkpoint Inhibitors+3 | Dr Kristen K CiomborDr John Strickler | — | — | Colorectal CancerImmune Checkpoint Inhibitors+3 | — | 50m 24s | ||
| 6/22/26 | Desmoid tumorsCryoablation+3 | Prof Bernd Kasper | — | — | desmoid tumorscryoblation+3 | — | 23m 46s | ||
| 6/19/26 | Gastroesophageal CancersAnti-PD-1/PD-L1 Antibodies+4 | Dr Yelena Y JanjigianDr Samuel J Klempner | — | — | gastroesophageal cancersanti-PD-1+5 | — | 50m 36s | ||
| 6/15/26 | Pancreatic CancerChemotherapy+3 | Dr Eileen M O’ReillyDr Philip A Philip | Pancreatic Cancer | — | pancreatic cancerchemotherapy+3 | — | 44m 49s | ||
| 6/2/26 | desmoid tumorstreatment strategies+1 | Prof Bernd Kasper | Mannheim Cancer Center | Mannheim, Germany | desmoid tumorstreatment+3 | — | 22m 50s | ||
| 5/28/26 | colorectal cancerclinical trials+3 | Dr Arvind DasariDr Anwaar Saeed | University of Texas MD Anderson Cancer CenterUPMC Hillman Cancer Center | HoustonPittsburgh | colorectal cancerclinical trials+3 | — | 58m 48s | ||
| 5/20/26 | immunotherapytargeted therapy+3 | Dr Jaffer A AjaniDr Rutika Mehta+1 | The University of Texas MD Anderson Cancer CenterWeill Cornell Medicine+2 | — | immunotherapytargeted therapy+5 | — | 8m 26s | ||
| 5/3/26 | localized colorectal cancerclinical findings+3 | Dr Stacey A CohenDr Jenny Seligmann+1 | Fred Hutchinson Cancer CenterUniversity of Leeds+1 | — | colorectal cancerASCO+5 | — | 18m 11s | ||
| 4/24/26 | immunotherapytargeted therapy+3 | Dr Jaffer AjaniDr Samuel Klempner+2 | The University of Texas MD Anderson Cancer CenterMassachusetts General Hospital+2 | — | immunotherapytargeted therapy+5 | — | 16m 54s | ||
| 4/13/26 | localized colorectal cancerclinical findings+3 | Dr Stacey A CohenDr Jenny Seligmann+1 | Fred Hutchinson Cancer CenterUniversity of Leeds+1 | — | colorectal cancerASCO+3 | — | 15m 06s | ||
| 4/8/26 | HER2-positive gastrointestinal cancersclinical management+3 | Dr Haley EllisProf Eric Van Cutsem+1 | Harvard Medical SchoolUniversity Hospitals Leuven+2 | — | HER2-positivegastrointestinal cancers+3 | — | 15m 45s | ||
| 4/7/26 | desmoid tumorsclinical data+3 | Dr Ravin Ratan | The University of Texas MD Anderson Cancer CenterGastrointestinal Cancer Update | — | desmoid tumorsclinical data+4 | — | 28m 14s | ||
| 4/3/26 | immunotherapytargeted therapy+3 | Dr Jaffer AjaniDr Samuel Klempner+2 | The University of Texas MD Anderson Cancer CenterMassachusetts General Hospital+2 | — | immunotherapytargeted therapy+4 | — | 22m 10s | ||
| 3/26/26 | localized colorectal cancerclinical findings+3 | Dr Stacey A CohenDr Jenny Seligmann+1 | Fred Hutchinson Cancer CenterUniversity of Leeds+1 | — | colorectal cancerASCO+3 | — | 17m 11s | ||
| 3/24/26 | immunotherapytargeted therapy+3 | Dr Jaffer AjaniDr Rutika Mehta+1 | The University of Texas MD Anderson Cancer CenterWeill Cornell Medicine/NewYork-Presbyterian Hospital+2 | — | immunotherapygastroesophageal cancer+3 | — | 24m 55s | ||
| 3/19/26 | HER2-positive gastrointestinal cancersclinical management+3 | Dr Haley EllisProf Eric Van Cutsem+1 | Harvard Medical SchoolUniversity Hospitals Leuven+2 | — | HER2-positivegastrointestinal cancers+3 | — | 21m 38s | ||
| 3/16/26 | desmoid tumorsclinical data+3 | Dr Ravin Ratan | The University of Texas MD Anderson Cancer CenterGastrointestinal Cancer Update | — | desmoid tumorsclinical data+3 | — | 16m 43s | ||
| 3/14/26 | HER2-positive gastrointestinal cancersmanagement perspectives+3 | Dr Haley EllisProf Eric Van Cutsem+1 | Mayo ClinicMass General Brigham Cancer Institute+2 | — | HER2-positivegastrointestinal cancers+5 | — | 12m 53s |
Showing 18 of 18
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Chart history for Gastrointestinal Cancer Update
Peaked at #180 in KE, currently #180 in KE.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| KE | — | #180 | #180 | — |
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.